Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss this phase II trial of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1–selected NSCLC (Abstract 17LBA).
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, summarizes his educational lecture on obesity, inflammation, and cancer—an important topic in oncology.
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: the efficacy and safety of pembrolizumab in previously treated non-small cell lung cancer (Abstract LBA33).
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses the results from a phase III study investigating a multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma (Abstract 17LBA).
As Chair of the ECC Local Organizing Committee, Christoph Zielinski, MD, of the Medical University Vienna - General Hospital, shares his thoughts on the important goals and presentations of the 2015 Congress.
Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses the latest developments in an important cancer treatment avenue.
